# Reviva Pharmaceuticals (RVPH) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RVPH
## Company Profile
- Ticker: RVPH
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS, Respiratory
## Stock Data
- Close: 0.4605 USD
- Market cap: Not available USD
- Last updated: 2026-08-12
## Business Overview
### Late-Stage CNS Company
Reviva Pharmaceuticals develops internally discovered therapies for central nervous system, inflammatory, and cardiometabolic diseases.
### Brilaroxazine
Brilaroxazine is the lead asset and is being advanced for schizophrenia. The compound has a broad serotonin and dopamine receptor profile intended to address positive, negative, mood, and cognitive symptoms.
### Lifecycle and Regulatory Strategy
Reviva has developed a new form of brilaroxazine intended to extend patent protection and plans to incorporate it into the RECOVER-2 registrational study and a future NDA.
## Why The Stock Is Moving

The latest monitored company update is “Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- FDA feedback on use of the new brilaroxazine form in RECOVER-2 and the future NDA is expected in mid-2026.
- Enrollment in the registrational Phase 3 RECOVER-2 schizophrenia trial is expected to begin in the third quarter of 2026.

## Recent News
- 2026-08-12 20:29 EST — [Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/RVPH/reviva-reports-second-quarter-2026-financial-results-and-recent-business-highlig-2c8ebd7b) — Source: Reviva Pharmaceuticals
- 2026-05-18 12:00 EST — [Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase](https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-fireside-chat-at-a-g-p-s-annual-healthcare-company-show-840282ca) — Source: Reviva Pharmaceuticals
- 2026-05-13 20:35 EST — [Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/RVPH/reviva-reports-first-quarter-2026-financial-results-and-recent-business-highligh-95d102d4) — Source: Reviva Pharmaceuticals
- 2026-04-23 12:00 EST — [Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications](https://biopharmsignal.com/news/RVPH/reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazine-s-pote-52ff9238) — Source: Reviva Pharmaceuticals
- 2026-04-15 12:00 EST — [Reviva Announces Letter to Shareholders](https://biopharmsignal.com/news/RVPH/reviva-announces-letter-to-shareholders-a6780413) — Source: Reviva Pharmaceuticals